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Introduction
Cervical cancer is the second most commonly diagnosed
cancer and the fourth leading cause of cancer death in
women worldwide, accounting for an estimated 275,000
deaths annually [1]. Cervical cancer develops over a long
period, progressing from premalignant and early-stage le-
sions called cervical intraepithelial neoplasia (CIN) to in-
vasive cancers. As a result, screening programs such as
cytologic screening have been able to detect pre-cancerous
and early-stage cervical cancer in young women. Further-
more, newer surgical options for early-stage disease have
allowed successful treatment and reduced cervical cancer
mortality. However, in medically underserved populations
with a poor healthcare infrastructure, the lack of regular
screening and effective treatment programs have resulted
in a disproportionately high burden of cervical cancer [1].
Multiple treatment options exist for early-stage cervical
lesions. The World Health Organization currently recom-
mends the treatment of CIN2 or CIN3 precancerous cervi-
cal lesions using loop electrosurgical excision procedure
(LEEP), conization, or hysterectomy. Of these modalities,
LEEP [2] is particularly attractive in low-resource settings
as it offers a “see and treat” option of simultaneously diag-
nosing and treating cases with abnormal Pap smear and col-
poscopic findings [3]. Furthermore, LEEP can be
performed easily and rapidly under local anesthesia in an
outpatient setting [4], and is associated with less blood loss
and fewer complications compared to conization [2]. For
example, obstetric complications, such as the risk of low
birth weight and preterm delivery, are increased after
conization [5-8], but not after LEEP [9].
In this study, the authors evaluated the safety and effi-
cacy of LEEP biopsy using a “see and treat” strategy and
compared outcomes after “see and treat” LEEP biopsy, in-
patient LEEP and ablation, and inpatient conization in a se-
ries of patients with CIN2/3 treated at a tertiary medical
center in Japan.
Materials and Methods
After obtaining approval from the institutional review board, a
retrospective review of medical records was performed for patients
with CIN2/3 treated consecutively between April 2011 and June
2015 at the Department of Obstetrics and Gynecology in the
Tokushima University Hospital, Japan. Inclusion criteria were
women aged under 50 years, with CIN2/3, who had not been pre-
viously treated for CIN, and who had been followed up for six-
months or longer. Exclusion criteria were women with CIN1 or
invasive carcinoma at the time of primary treatment, and cases
where hysterectomy was indicated as the initial treatment (Figure
1).
All cases underwent colposcopic evaluation and visualization of
lesions after application of 3% acetic acid for two minutes. Based
on colposcopic findings, patients were treated using one of three
strategies: 1) outpatient LEEP without anesthesia using a “see and
treat” strategy in patients with a narrow visible region of disease,
2) inpatient LEEP and ablation under local anesthesia in patients
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Summary
Purpose of investigation: To evaluate the safety and efficacy of loop electrosurgical excision procedure (LEEP) biopsy using a “see-
and-treat” strategy, and compare outcomes after “LEEP biopsy, inpatient LEEP and ablation, and inpatient conization with cervical in-
traepithelial neoplasia (CIN) grade 2/3. Materials and Methods: The authors performed a retrospective study including 300 women
with CIN2/3 who were followed up ≥ 6 months following outpatient LEEP/inpatient LEEP and ablation/inpatient conization. Recur-
rence, additional treatment for recurrence, pregnancy, and term delivery following treatment were evaluated. Results: During the me-
dian follow-up duration of 22 months, recurrences were significantly more common following LEEP biopsy (39%) compared to LEEP
and ablation (13%) and conization (16%) and were managed by repeat LEEP. Pregnancy and full-term delivery rates following LEEP
biopsy were significantly higher. Conclusion: “See-and-treat” LEEP biopsy was safely performed in the outpatient department. Preg-
nancy rates and full-term deliveries following LEEP biopsy appear favorable.
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with a wide visible region of disease, and 3) inpatient conization
with lumbar anesthesia in patients with unsatisfactory colposcopic
visualization and suspected wide region of disease (Figure 1).
“See and treat” LEEP biopsy was performed with a six-mm di-
ameter diathermal electrocauterizer after colposcopy without
anesthesia. LEEP and ablation was performed with YAG laser
under paracervical block and local anesthesia with 1% lidocaine.
Conization was performed using an ultrasonic energy device
under lumbar anesthesia.
Patients were followed up postoperatively at three, six, 12
months, and at 12-month intervals subsequently. Pap smear with
endocervical cytobrush and liquid-based cytology (LBC) were
performed at each follow-up. In the present hospital, HPV clear-
ance was not evaluated. When cytology showed negative findings
more than twice after primary LEEP or conization, the treatment
was considered to be curative. When abnormal cytological find-
ings were detected, colposcopy and biopsy were performed. If
CIN was detected, the case was defined as treatment failure.
The following data were collected during the retrospective re-
view: patient demographics - age, marital status, parity, and smok-
ing status, diagnosis, treatment, follow-up intervals, and
outcomes. The primary outcome of interest was recurrence, which
was defined as the reappearance of a lesion more than six months
after LEEP or conization. Additional treatment for the recurrence,
pregnancy after treatment, and term delivery were assessed as sec-
ondary outcomes of interest.
Statistical analyses were performed using R software. Differ-
ences in the frequency of the primary and secondary outcomes of
interest in the three tests groups were analyzed using tests for dif-
ference in ratios (prop.test function in R software). A p < 0.05 was
considered statistically significant.
The study was conducted under approval from the institutional
review board of Tokushima University Hospital. For this type of
study formal consent was not required. This article does not con-
tain any studies with animals performed by any of the authors.
Results
A total of 300 cases with LEEP or conization procedures
performed by four surgeons were included in the study. Pa-
tient characteristics are shown in Table 1. The median pa-
tient age was 34 (range, 19-49) years. One patient was a
teenager, 74 patients (25%) were in their 20s, 165 patients
(55%) in their 30s, and 60 patients (20%) in their 40s. Fifty-
six percent (169/300) of patients were non-smokers. With
regards to obstetric history, 143 patients (48%) had two or
more pregnancies and 111 patients (37%) had two or more
children. A total of 116 patients (39%) had CIN2, and 184
Table 1. — Patient demographics and operative details
(n=300)
Age (years; median, range) 34 (19-49)  
Obstetric status 0 1 2 ≥3 NA 
Gravidity 74 72 61 82 11  
Parity 110 68 78 33 11  
Smoking status 
Never smoked  169 (56%)  
Current smoker  90 (30%)  
Past smoker  13 (4%)  
Unknown  28 (10%)  
CIN grade 
CIN2  116 (39%)  
CIN3 184 (61%)  
Primary treatment 
LEEP biopsy 169 (56%)  
LEEP and ablation 99 (33%)  
Conization 32 (11%)  
Follow-up time 
(months; median, range)  22 (6-63)  
Data are presented as [median, range] for continuous variables and [number
(%)] for categorical variables. CIN: cervical intraepithelial neoplasia; LEEP:
loop electrosurgical excision procedure.
Figure 1. — Study design.
CIN: cervical intraepithelial neo-
plasia; LEEP: loop electrosurgical
excision procedure.
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patients (61%) had CIN3. “See and treat” LEEP biopsy was
performed in 169 cases (56%; CIN2, 89; CIN3, 80), LEEP
and ablation in 99 cases (33%; CIN2, 23; CIN3, 76), and
conization in 32 cases (11%; CIN2, 4; CIN3, 28). There
were no episodes of major bleeding or major infections
with any of the methods. The patients were followed-up for
a median duration of 22 (range, 6-63) months.
Treatment outcomes observed during follow-up are de-
scribed in Table 2. A total of 84 patients (28%) developed
recurrence (Table 2). Recurrences were significantly more
common after LEEP biopsy (39%) compared to LEEP and
ablation (13%) and conization (16%). The majority of re-
currences (19%) after LEEP biopsy occurred after 24
months of follow-up. In 15/66 patients with recurrence after
LEEP biopsy, the recurrent lesion was noted in the endo-
cervical canal and not at the external uterine orifice where
the original lesion was located. Patients with recurrences
were either managed conservatively (observation) or re-
ceived additional treatment (LEEP/conization/hysterec-
tomy).
Additional treatment was required in a significantly
higher proportion of patients after LEEP biopsy (41%)
compared to LEEP and ablation (15%) and conization
(16%). Of note, additional treatment after LEEP biopsy was
mostly in the form of repeat LEEP (28%) that was per-
formed in an outpatient (19%) or inpatient (9%) setting. In-
deed, additional treatment in the form of LEEP was
significantly more common in the LEEP biopsy group
(28%) compared to LEEP and ablation (1%) and coniza-
tion groups (3%). There were no significant differences in
the other modes of additional treatment among the three
groups. 
There were statistically significant differences in the rate
of pregnancies after treatment in the three groups. Preg-
nancy rates were significantly higher after LEEP biopsy
(26%) and conization (31%), compared to LEEP and abla-
tion (15%). However, induced abortions were significantly
more common after conization (16%), compared to LEEP
biopsy (0.6%) and LEEP and ablation (1%). In addition,
term delivery rates were significantly higher after LEEP
biopsy (20%) compared to LEEP and ablation (10%).
Discussion
The present authors’ aim in this study was to investigate
the safety and efficacy of “see and treat” LEEP biopsy and
compare its outcomes with inpatient LEEP and ablation,
and conization in patients with CIN2/3. In this five-year
retrospective study, nearly half (53%) of CIN2/3 cases in
patients under 50 years of age were treated with LEEP
biopsy without anesthesia in an outpatient setting. It is im-
portant to note that “see and treat” LEEP biopsy allowed
immediate diagnosis and treatment using LEEP without ob-
taining cervical biopsy specimens at the time of initial col-
poscopy [6]. Furthermore, compared to the traditional
punch biopsy that can examine only a small region and ex-
cise only very small lesions less than 1 cm, LEEP could ex-
cise lesions greater than 1 cm. Similar to cases receiving
LEEP and ablation or conization in an inpatient setting
under anesthesia, outpatient “see and treat” LEEP had no
immediate complications. These results suggest that LEEP
biopsy can be safely performed for CIN2/3 lesions in an
outpatient department. By avoiding anesthesia and hospi-
talization, LEEP biopsy potentially offers an economical
alternative both in terms of time and healthcare cost. The
present results are in agreement with those reported in a re-
Table 2. — Treatment outcomes in the three primary treatment groups.
LEEP biopsy (n=169) LEEP and ablation (n=99) Conization (n=32) 
Recurrence (n=84; 28%) 66 (39 %) 
a,b 
13 (13 %) 
a 
5 (16 %) 
b 
Under 12 months 19 (11%) 5 (5%) 0 (0%)  
12-24 months 15 (9%) 
c 
1 (1%) 
c,d 
4 (13%) 
d 
Over 24 months 32 (19%) 
e,f 
7 (7%) 
e 
1 (3%) 
f 
Additional treatment (n=89; 30%) 69 (41%) 
g,h 
15 (15%) 
g 
5 (16%) 
h 
LEEP 48 (28%) 
i,j 
1 (1%) 
i 
1 (3%) 
j 
Outpatient 33 (19%) 
k,l 
0 (0%) 
k 
0 (0%) 
l 
Inpatient 15 (9%) 
m 
1 (1%) 
m 
1 (3%)  
Conization 5 (3%) 3 (3%) 0 (0%)  
Hysterectomy 1 (0.6%) 2 (2%) 2 (6%)  
Observation (CIN1) 13 (8%) 6 (6%) 2 (6%)  
Development of invasive carcinoma 2 (1.2%) 3 (3%) 0 (0%) 
Pregnancy after treatment (n=69; 23%) 44 (26%) 
N 
15 (15%) 
N,O 
10 (31%) 
O 
Term delivery 34 (20%) 
p 
10 (10%) 
p 
5 (16%)  
Continuing pregnancy 4 (2.4%) 2 (2%) 0 (0%)  
Induced abortion 1 (0.6%) 
q 
1 (1%) 
r 
5(16%) 
q,r 
Preterm delivery 3 (1.8%) 0 (0%) 0 (0%)  
Spontaneous abortion 4 (2.4%) 2 (2%) 0 (0%)  
Lower case letters (a, b, etc.) indicate significant differences between groups. Upper case letters (N, O) indicate a strong trend of statistical significance (N: p =
0.054, O: p = 0.079). CIN: cervical intraepithelial neoplasia; LEEP: loop electrosurgical excision procedure.
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cent meta-analysis that showed that LEEP procedures were
faster, caused less intraoperative bleeding, and were asso-
ciated with shorter hospital stay compared to conization
[10]. However, recurrence rates in this study were higher
following “see and treat” LEEP biopsy than following
LEEP and ablation or conization. LEEP was performed
with ablative procedures in the ectocervical and endocer-
vical margins. Multiple fragmentation during LEEP af-
fected the assessment and interpretation of the margins.
This could potentially have resulted in the higher recur-
rence in this study. Nonetheless, it should be noted that
the majority of the recurrences could be managed by re-
peat LEEP. Indeed, there were no significant differences
between the three groups regarding the proportion of pa-
tients that had recurrence and required additional treat-
ment in the form of conization, hysterectomy, or were
managed by observation for CIN1 or who developed in-
vasive carcinoma. The rates of recurrence observed in this
study cohort were similar to those reported previously [4,
11, 12].
It should also be highlighted that nearly half of the re-
currences after LEEP biopsy occurred beyond 24 months
of follow-up. This is in contrast to conization where 80%
of the recurrences occur in the first 24 months. Indeed,
these results demonstrate the need for prolonged follow-
up of patients after outpatient LEEP biopsy. Previous
studies have provided conflicting opinions about the tim-
ing of recurrences following LEEP [13-15]. For example,
Cecchini et al. showed that recurrences were highest in
the first year (7.4%), and rare beyond the third year in a
study of Italian women with a 66.5-month average fol-
low-up [14]. Similarly, Carter et al. observed most recur-
rences occurred in the first year (3%) and only 1% beyond
one year of treatment in a cohort of Australian women
[15]. These differences in the rates and timing of recur-
rence might reflect differences in patient demographics
(age, disease status), surgical procedures, or surveil-
lance/follow-up protocols [16, 17]. For example, treat-
ment failure and recurrence rates have been linked to the
older age of patients, glandular involvement, and proce-
dural variations, such as excision of involved excision
margins [17]. 
Another notable observation was the location of the re-
current lesions following LEEP biopsy. In nearly one-
fourth of patients with recurrence after LEEP biopsy, the
recurrent lesion was noted in the endocervical canal and
not at the site of the original lesion at the external uterine
orifice. This suggests that the squamo-cutaneous junction
(SCJ) could move into the cervical canal following LEEP
and the recurrent lesions may, therefore, be missed during
colposcopy. This may be especially important for cases
that develop invasive carcinoma as advanced lesions were
found in the endocervical canal. When conducting a cyto-
diagnosis on a lesion in the endocervical canal, it is nec-
essary to properly insert a brush deeply inside.
Furthermore HPV test can be considered useful as an an-
cillary test.
As parity and smoking status are known to be risk fac-
tors for cervical cancer, the present authors examined the
smoking and parity status of the study population. Nearly
one-third of the study population had a parity ≥ 2 and cur-
rent or past history of smoking. Considering the young
age of the present study subjects (median age, 34 years),
hysterectomies were not included as a treatment option
and LEEP biopsy was preferred in most patients. Indeed,
the present results show that LEEP biopsy was associated
with significantly higher pregnancy rates (26%), lower in-
duced abortions (0.6%), and higher term delivery rates
(20%), compared to the other treatment options used in
the study. The present results are in agreement with pre-
vious studies showing no important adverse effects of
LEEP on fertility [9]. 
This study was not without limitations. First, this was a
single-center study based on the Japanese population.
Therefore, results from this study may not apply to other
populations or surgical practices. Second, the authors did
not monitor HPV infection and clearance status in the
study since these services are not covered by insurance in
Japan. Previous studies have shown that colposcopic de-
tection of HPV satellite lesions outside the transformation
zone and HPV persistence are independent factors for
treatment failure [16, 17]. Some authors recommend that
HPV-positive women after LEEP or conization require
close monitoring with HPV and Pap smear [18]. Future
studies should consider additional HPV testing as part of
monitoring and surveillance following LEEP [3, 13, 16,
17]. 
Conclusion
In conclusion, “see and treat” LEEP biopsy could be
performed safely without anesthesia in the outpatient de-
partment in women with CIN2/3 lesions. Recurrences
were largely managed by repeat LEEP and rates of preg-
nancy and full-term deliveries following LEEP biopsy
were higher than following LEEP and ablation or coniza-
tion. However, higher rates of recurrences, that occurred
late and often within the endocervical canal, highlights
the need for prolonged and careful monitoring of patients
following LEEP biopsy.
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